Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
US FDA approves Dupixent to treat younger kids with esophageal condition
02:48pm, Thursday, 25'th Jan 2024
The U.S. health regulator has approved the use of Regeneron and Sanofi's Dupixent to treat an allergic inflammation of the esophagus in children aged one to 11 years old and weighing at least 15 kg, t
3 Blue-Chip Healthcare Stocks to Buy and Hold Forever: January 2024
05:55pm, Tuesday, 23'rd Jan 2024
Blue-chip healthcare stocks tend to be among the top portfolio picks for long-term investors today. Though their blue-chip status implies maturity, which they have, it also implies that the companies
S&P 500 Index Hits All-Time High: 5 Must-Buy Stocks
09:11am, Monday, 22'nd Jan 2024
We have narrowed our search to five S&P 500 stocks that have strong growth potential in 2024. These are: NVDA, REGN, ANET, IT, MLM.
Regeneron (REGN), Sanofi's Dupixent Gets Label Update in US
12:26pm, Wednesday, 17'th Jan 2024
The FDA updates Regeneron (REGN) and Sanofi's Dupixent label in the United States to include efficacy and safety data for patients aged 12 years and older with atopic dermatitis with uncontrolled mode
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
01:51pm, Tuesday, 16'th Jan 2024
Biotech stocks, and the sector in general, saw a widespread beat down over the past two years. Venture capital dried up, post-pandemic healthcare landscapes shifted, and regulatory clampdowns tightene
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know
01:32pm, Friday, 12'th Jan 2024
Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 health care stocks off to strong starts in 2024
07:01am, Wednesday, 10'th Jan 2024
Up 2% five trading days into the new year, global health care stocks have already matched their return for all of 2023. It's very early, but the sector has outpaced all other 10 economic groups since
AI is the big thing right now, but the real tool is genetics, says Regeneron CEO Dr. Schleifer
08:20pm, Tuesday, 09'th Jan 2024
Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.
Regeneron CEO: We want to retain efficacy and eliminate bad side effects with our cancer treatments
08:13pm, Tuesday, 09'th Jan 2024
Regeneron CEO Dr. Leonard Schleifer joins 'Mad Money' host Jim Cramer to talk cancer treatments, quarterly earnings, weight loss medication and more.
Regeneron CEO says the next big thing for biotech isn't AI, it's gene therapy
07:12pm, Tuesday, 09'th Jan 2024
Regeneron CEO Leonard Schleifer detailed the biotech company's newest ventures in the pharmaceutical industry.
Regeneron (REGN) Down as Q4 Eylea Preliminary Sales Disappoint
12:47pm, Tuesday, 09'th Jan 2024
Regeneron (REGN) shares decline after it announces preliminary Q4 sales for the ophthalmology drug Eylea.
Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
08:25pm, Monday, 08'th Jan 2024
Regeneron Pharmaceuticals Inc. (REGN) 42nd Annual JPMorgan Healthcare Conference - (Transcript)
Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)
06:51pm, Monday, 08'th Jan 2024
Regeneron Pharmaceuticals, Inc.'s shares have risen over 25% in recent months, reaching over $910 per share - a premium explained partly by share buybacks. The company's market cap is around $100 bill
Regeneron hints at 4Q US sales of Eylea below expectations
01:42pm, Monday, 08'th Jan 2024
Regeneron Pharmaceuticals (NASDAQ:REGN) shares fell over 3% in early Monday afternoon trading after it told investors that US net product sales of its franchise of Eylea totalled about $1.46 billion
5 Stocks in S&P 500 ETF That Braved the Worst Start Since 2016
12:47pm, Monday, 08'th Jan 2024
The S&P 500 had the worst start to a year since 2016, reflecting a sharp reversal of the roaring rally in the final two months of 2023. Despite the losses, some stocks in the ETF stood tall.
